Why the study?
Do load-independent indices of left ventricular contractility improve the recognition of early myocardial impairment in patients receiving doxorubicin compared to standard indices?
Do load-independent indices of left ventricular contractility improve the recognition of early myocardial impairment in patients receiving doxorubicin compared to standard indices?
Load-independent indices of left ventricular contractility, such as the Pes-Des slope and sigma es-% delta D relation, are superior to standard fractional shortening for detecting early doxorubicin-induced myocardial impairment.
Answers are grounded in this paper and cite their sources.
Load-independent indices may aid early doxorubicin cardiotoxicity detection; hypothesis-generating and requires prospective validation.
The usual indices of left ventricular systolic performance have been incapable of accurately recognizing early myocardial impairment in many patients treated with doxorubicin. Recently, several new load-independent, highly sensitive indices of left ventricular contractility have been developed including the slope value of the endsystolic pressure (Pes)-dimension (Des) relation and the position of the left ventricular end-systolic wall stress (sigma es)-percent fractional shortening (% delta D) relation. We used these indices to study 46 patients receiving either low dose or high dose doxorubicin. Results were compared with data from 30 healthy subjects. Resting % delta D failed to accurately recognize left ventricular dysfunction in 9 of 17 patients with low normal values. These patients had reduced afterload, as measured by sigma es, permitting normal extent of left ventricular fiber shortening despite impaired contractility as quantified by diminished Pes-Des slope values. There was 98% concordance between the relative position of the sigma es-% delta D relation and the slope value of the Pes-Des, relation. These indices offer an improved means of recognizing and quantitating impaired contractility in patients treated with doxorubicin.
No takes yet. Share an insight, caveat, or question.
Borow et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: